PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease-Reference-Cited by-同舟云学术

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease

Published:2003-05 Issue:5 Volume:3 Page:459-469
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Cools Jan,Stover Elizabeth H,Boulton Christina L,Gotlib Jason,Legare Robert D,Amaral Sonia M,Curley David P,Duclos Nicole,Rowan Rebecca,Kutok Jeffery L,Lee Benjamin H,Williams Ifor R,Coutre Steven E,Stone Richard M,DeAngelo Daniel J,Marynen Peter,Manley Paul W,Meyer Thomas,Fabbro Doriano,Neuberg Donna,Weisberg Ellen,Griffin James D,Gilliland D.Gary

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference43 articles.

1. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251;Andrejauskas-Buchdunger;Cancer Res.,1992

2. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta;Apperley;N. Engl. J. Med.,2002

3. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate;Ault;Leuk. Res.,2002

4. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA;Baxter;Hum. Mol. Genet.,2002

5. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders;Baxter;Br. J. Haematol.,2003

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-03-29

2. Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs;International Journal of Molecular Sciences;2023-03-18

3. World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management;American Journal of Hematology;2021-10-08

4. T‐lymphoblastic lymphoma and acute myeloid leukaemia transformed from myeloid neoplasm with eosinophilia: a divergent evolution of myeloid neoplasm with monosomy 7 but no detectable tyrosine kinase gene rearrangements designated by the WHO Classification;British Journal of Haematology;2020-06-11

5. Management of Hematologic Disease in Mastocytosis;Mastocytosis;2019-12-02